The sub-lethal effects and tissue concentration of the human pharmaceutical atenolol in rainbow trout (Oncorhynchus mykiss)

Science of the Total Environment

Volumn 497-498, Issue , 2014, Pages 209-218

  Steinbach, Christoph ^a   Burkina, Viktoriia ^a   Fedorova, Ganna ^a   Grabicova, Katerina ^a   Stara, Alzbeta ^a   Velisek, Josef ^a   Zlabek, Vladimir ^a   Schmidt Posthaus, Heike ^b   Grabic, Roman ^a   Kocour Kroupova, Hana ^a  

^a UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antioxidant enzymes; Biochemical markers; Bioconcentration; Haematological parameters; Histopathological changes; Blockers

Indexed keywords

ANTIOXIDANTS; BIOACCUMULATION; BIOCHEMISTRY; ENVIRONMENTAL IMPACT; ENZYMES; OXYGEN; TISSUE; TOXICITY;

ANTIOXIDANT ENZYME; BIOCHEMICAL MARKERS; BIOCONCENTRATION; HAEMATOLOGICAL PARAMETERS; HISTOPATHOLOGICAL CHANGES;

BLOOD;

ATENOLOL; CATALASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B; CYTOCHROME P450 3A; GLUCOSE; GLUTATHIONE REDUCTASE; HEMOGLOBIN; LACTIC ACID; SUPEROXIDE DISMUTASE; ANTIHYPERTENSIVE AGENT; WATER POLLUTANT;

ANTIOXIDANT; BIOACCUMULATION; BLOOD; CONCENTRATION (COMPOSITION); DRUG; ECOTOXICOLOGY; ENZYME ACTIVITY; HEMOGLOBIN; HISTOLOGY; SALMONID; SUBLETHAL EFFECT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BIOCHEMICAL COMPOSITION; BLOOD SAMPLING; CHRONIC TOXICITY; CONTROLLED STUDY; DETOXIFICATION; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GROWTH RATE; HEART MUSCLE; HEMATOCRIT; HISTOPATHOLOGY; LETHALITY; LEUKOCYTE COUNT; LIMIT OF QUANTITATION; LIVER CONGESTION; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NONHUMAN; OXIDATIVE STRESS; PERICARDIUM; RAINBOW TROUT; TISSUE SPECIFICITY; TOXICITY TESTING; ANIMAL; METABOLISM; TOXICITY; WATER POLLUTANT;

ONCORHYNCHUS MYKISS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CATALASE; GLUTATHIONE REDUCTASE; ONCORHYNCHUS MYKISS; SUPEROXIDE DISMUTASE; WATER POLLUTANTS, CHEMICAL;

EID: 84905718758     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2014.07.111     Document Type: Article

References (79)

1. Aebi H. Catalase in vitro. Methods Enzym 1984, 105:121-126.
2. Bandyopadhyay S., Klaunig J.E., Somani P. Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture. Hepatology 1990, 1:48-58.
3. Bettge K., Wahli T., Segner H., Schmidt-Posthaus H. Proliferative kidney disease in rainbow trout: time- and temperature-related renal pathology and parasite distribution. Dis Aquat Organ 2009, 83:67-76.
4. Boillot O., Scoazec J.Y. Atenolol hepatotoxicity: report of a complicated case. Ann Pharmacother 2009, 43:1719-1723.
5. Burkina V., Zˇla´bek V., Zamaratskaia G. Clotrimazole, but not dexamethasone, is a potent in vitro inhibitor of cytochrome P450 isoforms CYP1A and CYP3A in rainbow trout. Chemosphere 2013, 92:1099-1104.
6. Carlberg I., Mannervik B. Purification and characterization of flavoenzyme glutathione reductase from rat-liver. J Biol Chem 1975, 250:5475-5480.
7. Corcoran J., Winter M.J., Tyler C.R. Pharmaceuticals in the aquatic environment: a critical review of the evidence for health effects in fish. Crit Rev Toxicol 2010, 40:287-304.
8. Corcoran J.A., Lange A., Winter M.J., Tyler C.R. Effects of pharmaceuticals on the expression of genes involved in detoxification in a carp primary hepatocyte model. Environ Sci Technol 2012, 46:6306-6314.
9. Daneshvar A., Svanfelt J., Kronberg L., Prevost M., Weyhenmeyer G.A. Seasonal variations in the occurrence and fate of basic and neutral pharmaceuticals in a Swedish river-lake system. Chemosphere 2010, 80:301-309.
10. The physiology of fishes 1997, 449. CRC Press, Boca Raton. 2nd ed. D.H. Evans (Ed.).
11. Ewing J.F., Janero D.R. Microplate superoxide dismutase assay employing a nonenzymatic superoxide generator. Anal Biochem 1995, 232:243-248.
12. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 2006, 76:122-159.
13. Fernandez C., Carbonell G., Babin M. Effects of individual and a mixture of pharmaceuticals and personal-care products on cytotoxicity, EROD activity and ROS production in a rainbow trout gonadal cell line (RTG-2). J Appl Toxicol 2013, 11:1203-1212.
14. Fick J., Lindberg R.H., Tysklind M., Larsson D.G. Predicted critical environmental concentrations for 500 pharmaceuticals. Regul Toxicol Pharmacol 2010, 58:516-523.
15. Flockhart D.A., Tanus-Santos J.E. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002, 162:405-412.
16. Frishman W.H. Beta-adrenergic blockers. Circulation 2003, 107:117-119.
17. Golovko O., Kumar V., Fedorova G., Randak T., Grabic R. Removal and seasonal variability of selected analgesics/anti-inflammatory, anti-hypertensive/cardiovascular pharmaceuticals and UV filters in wastewater treatment plant. Environ Sci Pollut Res 2014, 21:7578-7585.
18. Grabic R., Fick J., Lindberg R.H., Fedorova G., Tysklind M. Multi-residue method for trace level determination of pharmaceuticals in environmental samples using liquid chromatography coupled to triple quadrupole mass spectrometry. Talanta 2012, 100:183-195.
19. Grabicova K., Fedorova G., Burkina V., Steinbach C., Schmidt-Posthaus H., Zlabek V., et al. Presence of UV filters in surface water and the effects of phenylbenzimidazole sulfonic acid on rainbow trout (Oncorhynchus mykiss) following a chronic toxicity test. Ecotoxicol Environ Saf 2013, 96:41-47.
20. Gunnarsson L., Jauhiainen A., Kristiansson E., Nerman O., Larsson D.G.J. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. Environ Sci Technol 2008, 42:5807-5813.
21. Hampel M., Aparicio E., Bron J.E., Santos J.L., Taggart J.B., Leaver M.J. Potential physiological effects of pharmaceutical compounds in Atlantic salmon (Salmo salar) implied by transcriptomic analysis. Environ Sci Pollut Res 2010, 17:917-933.
22. Hasler J.A., Estabrook R., Murray M., Pikuleva I., Waterman M., Capdevila J., et al. Human cytochromes P450. Mol Aspects Med 1999, 20:1-137.
23. Henrion J. Hypoxic hepatitis. Liver Int 2012, 32:1039-1052.
24. Huggett D.B., Cook J.C., Ericson J.F., Williams R.T. A theoretical model for utilizing mammalian pharmacology and safety data to prioritize potential impacts of human pharmaceuticals to fish. Hum Ecol Risk Assess 2003, 9:1789-1799.
25. Ings J.S., George N., Peter M.C., Servos M.R., Vijayan M.M. Venlafaxine and atenolol disrupt epinephrine-stimulated glucose production in rainbow trout hepatocytes. Aquat Toxicol 2012, 106-107:48-55.
26. Pharma-ecology: the occurrence and fate of pharmaceuticals and personal care products in the environment 2008, 16-19. John Wiley & Sons, Inc., New Jersey. P.J. Jjemba (Ed.).
27. Jones O.A.H., Voulvoulis N., Lester J.N. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res 2002, 36:5013-5022.
28. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
29. Kennedy S.W., Jones S.P. Simultaneous measurement of cytochrome P4501A catalytic activity and total protein concentration with a fluorescence plate reader. Anal Biochem 1994, 222:217-223.
30. Khan G.A., Lindberg R., Grabic R., Fick J. The development and application of a system for simultaneously determining anti-infectives and nasal decongestants using on-line solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2012, 66:24-32.
31. Kim J.W., Ishibashi H., Yamauchi R., Ichikawa N., Takao Y., Hirano M., et al. Acute toxicity of pharmaceutical and personal care products on freshwater crustacean (Thamnocephalus platyurus) and fish (Oryzias latipes). J Toxicol Sci 2009, 34:227-232.
32. Komala P.T., Sankar P., Malliga S. Comparative study of antihypertensive treatment with enalapril and atenolol on oxidative stress and insulin resistance in essential hypertension. J Pharm Biol Sci 2013, 5:8-11.
33. Ku¨ster A., Alder A.C., Escher B.I., Duis K., Fenner K., Garric J., et al. Environmental risk assessment of human pharmaceuticals in the European Union: a case study with the β-blocker atenolol. Integr Environ Assess Manag 2010, 6:14-23.
34. Laville N., Ait-Aissa S., Gomez E., Casellas C., Porcher J.M. Effects of human pharmaceuticals on cytotoxicity, EROD activity and ROS production in fish hepatocytes. Toxicology 2004, 196:41-55.
35. Effects of pollution on fish molecular effects and population responses 2003, 17. Blackwell Science Ltd., Oxford. A. Lawrence, K. Hemingway (Eds.).
36. Lewis D.F.V. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology 2000, 144:197-203.
37. Lewis D.F.V. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004, 5:305-318.
38. Lushchak V. Environmentally induced oxidative stress in aquatic animals. Aquat Toxicol 2011, 101:13-30.
39. Machova J., Prokesˇ M., Kroupova´ H., Svobodova´ Z., Ma´cova´ S., Dolezˇelova´ P. Early ontogeny, growth and mortality of common carp (Cyprinus carpio) at low concentrations of dimethyl sulfoxide. Acta Vet Brno 2009, 78:505-512.
40. Massarsky A., Trudeau V.L., Moon T.W. β-Blockers as endocrine disruptors: the potential effects of human β-blockers on aquatic organisms. J Exp Zool A Ecol Genet Physiol 2011, 315:251-265.
41. Maurer M., Escher B.I., Richle P., Schaffner C., Alder A.C. Elimination of β-blockers in sewage treatment plants. Water Res 2007, 41:1614-1622.
42. Mehvar R., Brocks D.R. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 2001, 4:185-200.
43. Morel Y., Barouki R. Repression of gene expression by oxidative stress. Biochem J 1999, 342:481-496.
44. Nickerson J.G., Dugan S.G., Drouin G., Moon T.W. A putative beta(2)-adrenoceptor from the rainbow trout (Oncorhynuchus mykiss) - molecular characterization and pharmacology. Eur J Biochem 2001, 268:6465-6472.
45. Nickerson J.G., Drouin G., Perry S.F., Moon T.W. In vitro regulation of β-adrenoceptor signaling in the rainbow trout, Oncorhynchus mykiss. Fish Physiol Biochem 2002, 27:157-171.
46. Nunes B., Gaio A.R., Carvalho F., Guilhermino L. Behaviour and biomarkers of oxidative stress in Gambusia holbrooki after acute exposure to widely used pharmaceuticals and a detergent. Ecotoxicol Environ Saf 2008, 71:341-354.
47. OECD, Organization for Economic Cooperation and Development Guidelines for the testing of chemicals. Section 3: degradation and accumulation TG - No. 305: bioaccumulation in fish: aqueous and dietary exposure 2012, Organization for Economic Co-operation and Development.
48. Omura T., Sato R. The carbon monooxide-binding pigment of liver microsomes: I. Evidence for its hemoprotein nature. J Biol Chem 1964, 239:2370-2378.
49. Owen S.F., Giltrow E., Huggett D.B., Hutchinson T.H., Saye J., Winter M.J., et al. Comparative physiology, pharmacology and toxicology of [beta]-blockers: mammals versus fish. Aquat Toxicol 2007, 82:145-162.
50. Owen S.F., Huggett D.B., Hutchinson T.H., Hetheridge M.J., Kinter L.B., Ericson J.F., et al. Uptake of propranolol, a cardiovascular pharmaceutical, from water into fish plasma and its effects on growth and organ biometry. Aquat Toxicol 2009, 93:217-224.
51. Parks L.G., LeBlanc G.A. Involvement of multiple biotransformation processes in the metabolic elimination of testosterone by juvenile and adult fathead minnows (Pimephales promelas). Gen Comp Endocrinol 1998, 112:69-79.
52. Powell M.D., Burke M.S., Dahle D. Cardiac remodelling, blood chemistry, haematology and oxygen consumption of Atlantic cod, Gadus morhua L., induced by experimental haemolytic anaemia with phenylhydrazine. Fish Physiol Biochem 2011, 37:31-41.
53. Prichard B.N.C., Cruickshank J.M., Graham B.R. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press 2001, 10:366-386.
54. Rand-Weaver M., Margiotta-Casaluci L., Patel A., Panter G.H., Owen S.F., Sumpter J.P. The read-across hypothesis and environmental risk assessment of pharmaceuticals. Environ Sci Technol 2013, 47:11384-11395.
55. Reeves P.R., Mc Ainsh J., Mc Intosh D.A., Winrow M.J. Metabolism of atenolol in man. Xenobiotica 1978, 8:313-320.
56. Renwick A.B., Surry D., Price R.J., Lake B.G., Evans D.C. Metabolism of 7-benzyloxy-4-trifluoromethylcoumarin by human hepatic cytochrome P450 isoforms. Xenobiotica 2000, 30:955-969.
57. The toxicology of fishes 2008, 607. CRC Press, New York. T. Richard, D. Giulio, D.E. Hinton (Eds.).
58. RxList RxList-the internet drug index on, [accessed 17th March 2013]. http://www.rxlist.com.
59. Schmidt-Posthaus H., Steiner P., Muller B., Casanova-Nakayama A. Complex interaction between proliferative kidney disease, water temperature and concurrent nematode infection in brown trout. Dis Aquat Organ 2013, 104:23-34.
60. Schulz M., Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 2003, 58:447-474.
61. Sieroslawska A., Rymuszka A., Velisek J., Pawlik-Skowron´ska B., Svobodova Z., Skowron´ski T. Effects of microcystin-containing cyanobacterial extract on hematological and biochemical parameters of common carp (Cyprinus carpio L.). Fish Physiol Biochem 2012, 38:1159-1167.
62. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150:76-85.
63. Srikanth K., Pereira E., Duarte A.C., Ahmad I. Glutathione and its dependent enzymes' modulatory responses to toxic metals and metalloids in fish-a review. Environ Sci Pollut Res 2013, 20:2133-2149.
64. Stara A., Machova J., Velisek J. Effect of chronic exposure to simazine on oxidative stress and antioxidant response in common carp (Cyprinus carpio L.). Environ Toxicol Pharmacol 2012, 33:334-343.
65. Svobodova Z., Pravda D., Palackova J. Unified methods of haematological examination of fish. Methods 1991, 20:1-31. Research Institute of Fish Culture and Hydrobiology, Vodnany.
66. The State Institute for Drug Control (Czech Republic) on, [accessed 24th June 2014]. http://www.sukl.eu.
67. Uno T., Ishizuka M., Itakura T. Cytochrome P450 (CYP) in fish. Environ Toxicol Pharmacol 2012, 34:1-13.
68. US EPA Estimation Programs Interface Suite™ for Microsoft® Windows, v 4.11 2012, United States Environmental Protection Agency, Washington, DC, USA, [http://www.epa.gov/opptintr/exposure/pubs/episuite.htm].
69. Valdes M.E., Ame M.V., Bistoni Mde L., Wunderlin D.A. Occurrence and bioaccumulation of pharmaceuticals in a fish species inhabiting the Suquia River basin (Cordoba, Argentina). Sci Total Environ 2014, 472:389-396.
70. van Den Thillart G., Vianen G., Campos Ponce M., Lelieveld H., Nieveen H., Raaij Van, et al. Differential role of adrenoceptors in control of plasma glucose and fatty acids in carp, Cyprinus carpio (L.). Am J Physiol Regul Integr Comp Physiol 2001, 281:615-624.
71. van der Oost R., Beyer J., Vermeulen N.P.E. Fish bioaccumulation and biomarkers in environmental risk assessment: a review. Environ Toxicol Pharmacol 2003, 13:57-149.
72. Velisek J., Sudova E., Machova J., Svobodova Z. Effects of sub-chronic exposure to terbutryn in common carp (Cyprinus carpio L.). Ecotoxicol Environ Saf 2010, 73:384-390.
73. Vieno N.M., Tuhkanen T., Kronberg L. Analysis of neutral and basic pharmaceuticals in sewage treatment plants and in recipient rivers using solid phase extraction and liquid chromatography-tandem mass spectrometry detection. J Chromatogr A 2006, 1134:101-111.
74. Vieno N., Tuhkanen T., Kronberg L. Elimination of pharmaceuticals in sewage treatment plants in Finland. Water Res 2007, 41:1001-1012.
75. Wander G.S., Chhabra S.T., Kaza K. Atenolol drug profile. J Assoc Physicians India Suppl 2009, 57:13-16.
76. Wiegand C., Pflugmacher S., Oberemm A., Steinberg C. Activity development of selected detoxification enzymes during the ontogenesis of the zebrafish (Danio rerio). Int Rev Hydrobiol 2000, 85:413-422.
77. Winter M.J., Lillicrap A.D., Caunter J.E., Schaffner C., Alder A.C., Ramil M., et al. Defining the chronic impacts of atenolol on embryo-larval development and reproduction in the fathead minnow (Pimephales promelas). Aquat Toxicol 2008, 86:361-369.
78. Yamamoto H., Nakamura Y., Moriguchi S., Nakamura Y., Honda Y., Tamura I., et al. Persistence and partitioning of eight selected pharmaceuticals in the aquatic environment: laboratory photolysis, biodegradation, and sorption experiments. Water Res 2009, 43:351-362.
79. Zuccato E., Castiglioni S., Fanelli R., Reitano G., Bagnati R., Chiabrando C., et al. Pharmaceuticals in the environment in Italy: causes, occurrence, effects and control. Environ Sci Pollut Res Int 2006, 13:15-21.